Net Income (Loss) Attributable to Parent in USD of AVADEL PHARMACEUTICALS PLC from 2010 to Q3 2025

Taxonomy & unit
us-gaap: USD
Description
The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.
Summary
AVADEL PHARMACEUTICALS PLC quarterly/annual Net Income (Loss) Attributable to Parent history and change rate from 2010 to Q3 2025.
  • AVADEL PHARMACEUTICALS PLC Net Income (Loss) Attributable to Parent for the quarter ending 30 Sep 2025 was $20M.
  • AVADEL PHARMACEUTICALS PLC Net Income (Loss) Attributable to Parent for the twelve months ending 30 Sep 2025 was $19.7M.
  • AVADEL PHARMACEUTICALS PLC annual Net Income (Loss) Attributable to Parent for 2024 was -$48.8M, a 69.5% increase from 2023.
  • AVADEL PHARMACEUTICALS PLC annual Net Income (Loss) Attributable to Parent for 2023 was -$160M, a 16.6% decline from 2022.
  • AVADEL PHARMACEUTICALS PLC annual Net Income (Loss) Attributable to Parent for 2022 was -$137M, a 77.8% decline from 2021.
Net Income (Loss) Attributable to Parent, Trailing 12 Months (USD)
Net Income (Loss) Attributable to Parent, Quarterly (USD)
Net Income (Loss) Attributable to Parent, YoY Quarterly Change (%)
Net Income (Loss) Attributable to Parent, Annual (USD)
Net Income (Loss) Attributable to Parent, YoY Annual Change (%)

AVADEL PHARMACEUTICALS PLC Quarterly Net Income (Loss) Attributable to Parent (USD)

Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q3 2025 $19.7M $20M +$22.6M 01 Jul 2025 30 Sep 2025 10-Q 04 Nov 2025
Q2 2025 -$2.92M $9.67M +$23.5M 01 Apr 2025 30 Jun 2025 10-Q 04 Nov 2025
Q1 2025 -$26.4M -$4.92M +$22.4M +82% 01 Jan 2025 31 Mar 2025 10-Q 04 Nov 2025
Q4 2024 -$48.8M -$5.04M +$23.7M +82.5% 01 Oct 2024 31 Dec 2024 10-K 03 Mar 2025
Q3 2024 -$72.6M -$2.63M +$33.6M +92.8% 01 Jul 2024 30 Sep 2024 10-Q 04 Nov 2025
Q2 2024 -$106M -$13.8M +$50.6M +78.5% 01 Apr 2024 30 Jun 2024 10-Q 04 Nov 2025
Q1 2024 -$157M -$27.3M +$3.44M +11.2% 01 Jan 2024 31 Mar 2024 10-Q 04 Nov 2025
Q4 2023 -$160M -$28.8M -$1.34M -4.87% 01 Oct 2023 31 Dec 2023 10-K 03 Mar 2025
Q3 2023 -$159M -$36.3M -$16.1M -80.1% 01 Jul 2023 30 Sep 2023 10-Q 12 Nov 2024
Q2 2023 -$143M -$64.4M -$988K -1.56% 01 Apr 2023 30 Jun 2023 10-Q 12 Nov 2024
Q1 2023 -$142M -$30.8M -$4.36M -16.5% 01 Jan 2023 31 Mar 2023 10-Q 12 Nov 2024
Q4 2022 -$137M -$27.5M -$5.15M -23.1% 01 Oct 2022 31 Dec 2022 10-K 03 Mar 2025
Q3 2022 -$132M -$20.1M +$1.86M +8.44% 01 Jul 2022 30 Sep 2022 10-Q 08 Nov 2023
Q2 2022 -$134M -$63.4M -$43.9M -224% 01 Apr 2022 30 Jun 2022 10-Q 08 Nov 2023
Q1 2022 -$90.3M -$26.4M -$13M -96.5% 01 Jan 2022 31 Mar 2022 10-Q 08 Nov 2023
Q4 2021 -$77.3M -$22.3M -$11M -97.7% 01 Oct 2021 31 Dec 2021 10-K 29 Feb 2024
Q3 2021 -$66.3M -$22M -$10.3M -88% 01 Jul 2021 30 Sep 2021 10-Q 09 Nov 2022
Q2 2021 -$56M -$19.6M -$50.5M -163% 01 Apr 2021 30 Jun 2021 10-Q 09 Nov 2022
Q1 2021 -$5.55M -$13.4M -$12.6M -1454% 01 Jan 2021 31 Mar 2021 10-Q 09 Nov 2022
Q4 2020 $7.03M -$11.3M -$8.54M -312% 01 Oct 2020 31 Dec 2020 10-K 16 Mar 2022
Q3 2020 $15.6M -$11.7M -$2.84M -32% 01 Jul 2020 30 Sep 2020 10-Q 08 Nov 2021
Q2 2020 $18.4M $30.9M +$39.5M 01 Apr 2020 30 Jun 2020 10-Q 08 Nov 2021
Q1 2020 -$21.1M -$865K +$12.2M +93.4% 01 Jan 2020 31 Mar 2020 10-Q 08 Nov 2021
Q4 2019 -$33.2M -$2.74M +$61.1M +95.7% 01 Oct 2019 31 Dec 2019 10-K 16 Mar 2022
Q3 2019 -$94.3M -$8.86M +$6.91M +43.8% 01 Jul 2019 30 Sep 2019 10-Q 09 Nov 2020
Q2 2019 -$101M -$8.61M -$5.17M -150% 01 Apr 2019 30 Jun 2019 10-Q 09 Nov 2020
Q1 2019 -$96.1M -$13M -$782K -6.39% 01 Jan 2019 31 Mar 2019 10-Q 09 Nov 2020
Q4 2018 -$95.3M -$63.9M -$55.6M -675% 01 Oct 2018 31 Dec 2018 10-K 09 Mar 2021
Q3 2018 -$39.7M -$15.8M -$37.5M -173% 01 Jul 2018 30 Sep 2018 10-Q 12 Nov 2019
Q2 2018 -$2.24M -$3.44M -$32.4M -112% 01 Apr 2018 30 Jun 2018 10-Q 12 Nov 2019
Q1 2018 $30.1M -$12.2M -$38.1M -147% 01 Jan 2018 31 Mar 2018 10-Q 12 Nov 2019
Q4 2017 $68.3M -$8.25M -$13M -274% 01 Oct 2017 31 Dec 2017 10-K 16 Mar 2020
Q3 2017 $81.3M $21.7M +$41.7M 01 Jul 2017 30 Sep 2017 10-Q 05 Nov 2018
Q2 2017 $39.6M $28.9M +$48.9M 01 Apr 2017 30 Jun 2017 10-Q 07 Aug 2018
Q1 2017 -$9.31M $25.9M +$32M 01 Jan 2017 31 Mar 2017 10-Q 04 May 2018
Q4 2016 -$41.3M $4.73M -$70.4M -93.7% 01 Oct 2016 31 Dec 2016 10-K 15 Mar 2019
Q3 2016 $29.1M -$20M +$8.08M +28.8% 01 Jul 2016 30 Sep 2016 10-Q 09 Nov 2017
Q2 2016 $21M -$20M -$3.1M -18.4% 01 Apr 2016 30 Jun 2016 10-Q 09 Aug 2017
Q1 2016 $24.1M -$6.06M -$17.7M -152% 01 Jan 2016 31 Mar 2016 10-Q 10 May 2017
Q4 2015 $41.8M $75.1M +$103M 01 Oct 2015 31 Dec 2015 10-K 16 Mar 2018
Q3 2015 -$61M -$28.1M -$18M -179% 01 Jul 2015 30 Sep 2015 10-Q 14 Nov 2016
Q2 2015 -$43M -$16.9M +$4.22M +20% 01 Apr 2015 30 Jun 2015 10-Q 15 Aug 2016
Q1 2015 -$47.2M $11.6M +$38.3M 01 Jan 2015 31 Mar 2015 10-Q 10 May 2016
Q4 2014 -$85.5M -$27.7M -$32.8M -641% 01 Oct 2014 31 Dec 2014 10-K 28 Mar 2017
Q3 2014 -$52.6M -$10M -$3.68M -57.7% 01 Jul 2014 30 Sep 2014 6-K 17 Nov 2014
Q2 2014 -$49M -$21.1M +$11.8M +35.9% 01 Apr 2014 30 Jun 2014 6-K 31 Dec 2015
Q1 2014 -$60.7M -$26.6M -$17.8M -202% 01 Jan 2014 31 Mar 2014 6-K 10 Jul 2015
Q4 2013 -$42.9M $5.13M -$3.98M -43.7% 01 Oct 2013 31 Dec 2013 10-K 15 Mar 2016
Q3 2013 -$39M -$6.37M +$56K +0.87% 01 Jul 2013 30 Sep 2013 6-K 17 Nov 2014
Q2 2013 -$39M -$32.9M -$26.9M -455% 01 Apr 2013 30 Jun 2013 6-K 08 Aug 2014
Q1 2013 -$12.1M -$8.83M -$8.84M 01 Jan 2013 31 Mar 2013 6-K 08 Jul 2014
Q4 2012 -$3.23M $9.1M 01 Oct 2012 31 Dec 2012 20-F 01 Oct 2015
Q3 2012 -$6.43M 01 Jul 2012 30 Sep 2012 6-K 15 Jan 2014
Q2 2012 -$5.92M -$2.46M -71.1% 01 Apr 2012 30 Jun 2012 6-K 06 Dec 2013
Q1 2012 $12K* +$4.94M 01 Jan 2012 31 Mar 2012 6-K 13 Sep 2012
Q2 2011 -$3.46M 01 Apr 2011 30 Jun 2011 6-K 14 Dec 2012
Q1 2011 -$4.93M 01 Jan 2011 31 Mar 2011 6-K 13 Sep 2012

AVADEL PHARMACEUTICALS PLC Annual Net Income (Loss) Attributable to Parent (USD)

Period Value YoY Chg Change % Start Date End Date Report Filed
2024 -$48.8M +$111M +69.5% 01 Jan 2024 31 Dec 2024 10-K 03 Mar 2025
2023 -$160M -$22.8M -16.6% 01 Jan 2023 31 Dec 2023 10-K 03 Mar 2025
2022 -$137M -$60.1M -77.8% 01 Jan 2022 31 Dec 2022 10-K 03 Mar 2025
2021 -$77.3M -$84.4M -1200% 01 Jan 2021 31 Dec 2021 10-K 29 Feb 2024
2020 $7.03M +$40.3M 01 Jan 2020 31 Dec 2020 10-K 16 Mar 2022
2019 -$33.2M +$62.1M +65.1% 01 Jan 2019 31 Dec 2019 10-K 16 Mar 2022
2018 -$95.3M -$164M -240% 01 Jan 2018 31 Dec 2018 10-K 09 Mar 2021
2017 $68.3M +$110M 01 Jan 2017 31 Dec 2017 10-K 16 Mar 2020
2016 -$41.3M -$83.1M -199% 01 Jan 2016 31 Dec 2016 10-K 15 Mar 2019
2015 $41.8M +$127M 01 Jan 2015 31 Dec 2015 10-K 16 Mar 2018
2014 -$85.5M -$42.5M -99.1% 01 Jan 2014 31 Dec 2014 10-K 28 Mar 2017
2013 -$42.9M -$39.7M -1230% 01 Jan 2013 31 Dec 2013 10-K 15 Mar 2016
2012 -$3.23M +$5.55M +63.2% 01 Jan 2012 31 Dec 2012 20-F 01 Oct 2015
2011 -$8.77M +$201K +2.24% 01 Jan 2011 31 Dec 2011 20-F/A 30 Apr 2014
2010 -$8.98M 01 Jan 2010 31 Dec 2010 20-F 30 Apr 2013
* An asterisk sign (*) next to the value indicates that the value is likely invalid.